

1 Key factors contributing to gender inequity in global rheumatology awards: a global survey
2 analysis

3

4 Jessica Day^{1,2,3#}, Lekshmi Minikumari Rahulan^{4#}, Shikha Singla⁵, Praggya Yaadav⁶, Arsh E
5 Bareen Khan⁷, Debaditya Roy⁸, Vikas Agarwal⁴, Grace Wright⁹, Laura Andreoli¹⁰, Pavel
6 Ovseiko¹¹, Laura Coates¹², Latika Gupta^{13,14,15}, the CHANGE Study group.

7 # - Authors contributed equally

8

- 9 1. Department of Rheumatology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia.
- 10 2. Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052 Australia.
- 11 3. Department of Medical Biology, University of Melbourne, Parkville, VIC 3052 Australia.
- 12 4. Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate
13 Institute of Medical Sciences, Raebareli Road, Lucknow 226014, India.
- 14 5. Department of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, USA
- 15 6. Maharashtra Institute of Medical Sciences and Research, Latur, Maharashtra, India
- 16 7. Sree Balaji Medical College and Hospital, Chennai, India
- 17 8. Department of Clinical Immunology and Rheumatology, Institute of Postgraduate
18 Medical Education and Research, Kolkata, West Bengal, India
- 19 9. Association of Women in Rheumatology; Grace C Wright MD PC Inc., New York, NY,
20 USA.
- 21 10. Rheumatology and Clinical Immunology Unit, ASST Spedali, Civili and University of
22 Brescia, 25123, Brescia, Italy.
- 23 11. Radcliffe Department of Medicine, University of Oxford, Oxford, UK
- 24 12. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
25 University of Oxford, Oxford, UK

26 13. Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust,
27 Wolverhampton, WV10 0QP, UK.

28 14. School of Infection, Inflammation and Immunology, College of Medicine and Health,
29 University of Birmingham, UK.

30 15. The Francis Crick Institute, London, UK.

31

32 **Correspondence to**

33 Dr. Latika Gupta

34 Dept of Rheumatology, Royal Wolverhampton Trust, Wolverhampton, WV10 0QP, United

35 Kingdom. Orcid ID: 0000-0003-2753-2990

36 Email- drlatikagupta@gmail.com

37 +4401902 307999

38

39 **Acknowledgments:** The authors thank all respondents for taking the survey.

40

41 **Declarations:** LC leads the EULAR GEAR group, LG serves as diversity, equity, and inclusivity

42 ambassador for Therapeutic advances and practice.

43

44 **Funding:** This study was not funded.

45

46 **Conflicts of Interest/Competing interests:** The authors have no COI relevant to this
47 manuscript.

48

49 **Contribution of authors:**

50 Conceptualisation: PO, LC, LG. Data curation: All authors. Formal analysis: LMR, JD. Funding
51 acquisition: N/A. Investigation: All authors. Methodology: All authors. Validation: All Authors,
52 Visualisation: All authors, Writing-original draft: JD, SS, LMR. Writing-review & editing: All
53 authors.

54 **Data availability statement:** All relevant data are present in this correspondence piece.

55 **Disclaimer:** No part of this manuscript is copied or published elsewhere in whole or in part.

56 The views and opinions expressed are solely those of the author and do not represent or
57 reflect those of any affiliated institution.

58

59 **Keywords:** Gender inequity, Gender bias, Career awards

60

61 **Key Messages**

62 1. Women rheumatologists are underrepresented in leadership roles and prestigious
63 awards.

64 2. Women rheumatologists are less likely to receive career awards or serve in award
65 selection committees.

66 3. Domestic demands on women, lack of female nominees and limited visibility of
67 female candidates are contributory.

68

69

70 **Abstract**

71 **Background:** Despite increasing gender equity in the rheumatology workforce, disparities
72 persist in leadership roles and prestigious career awards.

73 **Objectives:** To identify key factors contributing to the under-representation of women
74 among recipients of prestigious career awards in rheumatology.

75 **Methods:** A 13-item e-survey was distributed to rheumatologists and allied health
76 professionals globally to identify factors contributing to gender disparity in award conferral.

77 **Results:** Among 227 respondents from 40 countries, 68.3% were female. The most
78 significant barrier identified was the competing demands of domestic responsibilities on
79 women (42.9%). Additional factors included a lack of female nominees (38.7%), limited
80 visibility of female candidates (38.3%), and fewer leadership opportunities (35.0%).

81 **Conclusion:** This study underscores the impact of domestic responsibilities and restricted
82 professional opportunities on gender inequity in rheumatology awards. These results call for
83 diversification of selection committees, enhanced transparency in nomination and accurate
84 assessment of the gender-specific impacts of career breaks on productivity.

85

86

87 **Introduction**

88 Despite increasing representation of women in the rheumatology clinical workforce,
89 leadership positions remain male-dominated¹. A growing body of literature indicates gender
90 disparities in various prestigious roles², including full or associate professorships³, editorial
91 boards of rheumatology journals⁴, senior authorship positions⁵, conference speakers⁶, and
92 presidents of rheumatology societies⁷. A recent study also identified a significant gender gap
93 in the conferral of major rheumatology awards, with male rheumatologists receiving 83% of
94 prestigious career awards⁸.

95 Prizes serve as one the highest forms of recognition among professionals, symbolically
96 highlighting outstanding individuals and showcasing the values of the rheumatology
97 profession to the broader community. Beyond recognising notable ideas or initiatives, awards
98 enhance the status of recipients, lending credibility to their work and positioning them as
99 successful role models. These recognitions have long-term career implications, influencing
100 promotions, funding, invited opportunities, collaborations and tenure. By shaping the future
101 trajectory of recipients, awards not only reward past achievements, but also drive the
102 direction of scientific investment and discovery.

103 Despite a proliferation of scientific prizes in recent times, their conferral remains
104 concentrated within a tightly connected scientific elite, influenced by social and professional
105 networks⁹. Gender homophily bias in scholarly teams formation may exacerbate these
106 disparities¹⁰. The underrepresentation of women in the distribution of prestigious awards can
107 perpetuate exclusion from key opportunities, hindering professional advancement and
108 reinforcing systemic gender inequity. To achieve gender balance in the conferral of
109 prestigious awards in rheumatology, it is essential to identify the key contributors to the

110 underrepresentation of women. We surveyed the rheumatology community to explore
111 factors underlying this gender disparity.

112 **Methods**

113 *Survey Design*

114 A 13-item e-survey captured participant characteristics, including demographics, professional
115 details, caregiving responsibilities and self-reported award recipient status. 'Prestigious
116 career awards' were defined as competitive awards conferred by national or international
117 rheumatology bodies or affiliated societies recognizing research, clinical excellence,
118 leadership or service (e.g., named lectureships, lifetime achievement/merit awards).
119 Respondents were asked to identify the most significant factors contributing to the under-
120 representation of women among award recipients from a list of 18 possible multi select
121 responses: 'Implicit gender biases in nominations and selections', 'Undervaluation of
122 women's contributions to the field', 'Lack of female nominees', 'Lack of transparency in
123 nomination and selection processes', 'Limited visibility of deserving female candidates', 'Lack
124 of female role models and award namesakes', 'Competing demands on women for domestic
125 responsibilities', 'Fewer leadership opportunities for women', 'Higher attrition rates for
126 women in academia/research careers', 'Age restrictions disproportionately affecting women
127 due to career disruptions', 'Geographic location limiting visibility, networking and
128 collaborations', 'Lack of dedicated mentoring and sponsorship programs', 'Gender norms and
129 expectations in society and within rheumatology', 'Inadequate institutional support for
130 pursuing career awards', 'Systematic biases in research funding and resource allocation',
131 'Disproportionate allocation of 'low visibility work' that may not lead to recognition or
132 promotion', 'Reduced access to influential circles and professional networks', and 'I am not
133 sure'. The questionnaire was developed by four rheumatologists and one gender equity policy

134 expert. Multiple rounds of dummy fill-ups were conducted to identify errors in wording and
135 syntax. The survey was partly anonymised with email addresses as the only linked identifiers.
136 Survey reporting followed CHERRIES standards for internet surveys¹¹.

137 *Sampling Strategy & Data Handling*

138 The survey was circulated via email and social media among the CHANGE group, previous
139 rheumatology award recipients, professional rheumatology networks and the broader
140 rheumatology community. The survey was voluntary and conducted from 22/02/2024 to
141 29/7/2024. Informed consent was obtained at the beginning of the survey, and no incentives
142 were offered for survey completion. Data were handled anonymously, with the email lists
143 remaining with the corresponding author. Approval was obtained from the Sanjay Gandhi
144 Postgraduate Institute of Medical Sciences Ethics Review Board (226014).

145 *Statistical analysis*

146 Responses are summarised using descriptive statistics and data are expressed as raw numbers
147 and percentages. Chi-squared was applied to compare groups for categorical variables.
148 Primary outcome of the survey was to identify perceived barriers to women's award receipt.
149 Additionally, in an exploratory model, logistic regression was used to identify determinants
150 of self-reported award receipt status. Incomplete survey responses were included in the
151 analysis if they provided data for the primary question: "*What are the most significant factors*
152 *contributing to the under-representation of women among recipients of prestigious career*
153 *awards in rheumatology.*" Primary analysis included respondents who answered the barriers
154 question, item level denominators (n/N, %) are shown for all descriptive results. For inferential
155 models, we conducted complete case analysis and report the modelling denominator explicitly.
156 Multivariate logistic regression was done for the exploratory model for award receipt.
157 Minimal adjustment set, informed by a directed acyclic graph (DAG) (Supplementary figure

158 1), included career stage, academic role (physician vs AHP), member of selection committee,
159 profession, care giver responsibilities, age, gender, marital status and WHO HDI category.
160 Ethnicity was excluded from the primary model and included in sensitivity analyses. We
161 verified events-per-variable and simplified models (reduced parameters and collapsed sparse
162 categories) where EPV<10. Estimates are presented as odds ratios with 95% CIs with emphasis
163 on effect sizes. . Statistical analysis was performed using STATA 17.0 (StataCorp, College
164 Station, TX, USA). Graphs were generated using GraphPad Prism 9.4.1 (GraphPad Software,
165 San Diego, CA, USA).

166

167 **Results**

168 This was an open, convenience and snowball sample disseminated via rheumatology societies,
169 professional networks and social media. Because invitations were not individualized, a response rate
170 could not be calculated. We received 227 responses spanning 40 countries and different classes of
171 human development index (HDI). However, the findings may not be representative of the global
172 workforce. Twenty-three incomplete responses were included in the final analysis as they
173 provided relevant data. The majority of respondents were Hispanic or Latino (43.6%) or
174 White (29.9%), and 68.3% were female (Table 1). Ninety four percent were physicians,
175 48.1% were mid-career, and 67% held academic positions.

176 *Perceived barriers to women's award receipt*

177 The most commonly identified barrier to gender equity in rheumatology awards by
178 respondents was the competing demands on women for domestic responsibilities, selected
179 by 42.9% of respondents (Figure 1). A higher proportion of female respondents identified this
180 factor as a critical barrier than male respondents (48.5% versus 27.4%, p=0.005). Females with
181 caregiving responsibilities were more likely to select this factor compared with respondents

182 without such responsibilities (51.4% versus 35.5%, $p=0.02$). Other commonly selected barriers
183 included: lack of female nominees (38.7%), limited visibility of deserving female candidates
184 (38.3%), fewer leadership opportunities for women (35%), under-evaluation of women's
185 contribution (30.3%), higher attrition rates for women in academia (17.3%) and geographic
186 location limiting visibility, networking and collaboration (24.3%).

187 Of note, a higher proportion of female respondents identified undervaluation of
188 women's contributions to the field (36.0% versus 17.7%, $p=0.009$) and reduced access to
189 influential circles and professional networks (25.7% versus 8.1%, $p=0.004$) as critical barriers.
190 Award recipients more frequently identified the disproportionate allocation of 'low visibility
191 work' (29.5% versus 16.6%, $p=0.04$) and higher attrition rates for women in academia (24.6%
192 versus 15.1%, $p=0.04$) as barriers compared with non-recipients. Males more commonly
193 indicated uncertainty about significant barriers by selecting 'I'm not sure' (11.3% versus 2.9%,
194 $p=0.02$).

195 *Determinants of award status*

196 Among male respondents, 39.7% had received a career award and 19.4% had served on an
197 award selection committee, compared with 24.2% and 10.5% of female respondents,
198 respectively. Dependent caregiving responsibilities did not significantly differ between
199 genders and did not correlate with self-reported award recipient status. In an exploratory
200 regression model, having an academic role (OR: 2.66 (1.01-7.03), $p=0.04$), age >60 years
201 (OR: 11.89, 95% CI: 2.29-61.8, $p=0.003$) and having served as a member of award selection
202 committee (OR: 3.41, 95% CI: 1.13-10.27, $p=0.02$) were associated with increased odds of
203 receiving an award (Supplementary Table 1). Sensitivity analyses with adjustment for
204 ethnicity (Supplementary table 2) and excluding non-physicians and those without an
205 academic role yielded similar results.

206 Discussion

207 This study identifies significant barriers to gender equity in prestigious rheumatology
208 awards. The most prominent barrier identified is the competing domestic responsibilities that
209 disproportionately burden women. This factor was highlighted by 42.9% of respondents, with
210 a higher proportion of females -particularly female caregivers- identifying it as a critical
211 barrier compared to male respondents or non-caregivers. This suggests that decision makers
212 who may have limited personal exposure to balancing intensive domestic and primary caregiving
213 responsibilities could potentially undervalue these constraints for applicants. Our findings reflect
214 perceived barriers and may not directly indicate causal determinants of award receipt.
215 Although our binary caregiver variable did not differ by gender nor correlate with self-
216 reported awards, the measure did not capture intensity, 'primary carer' status, or time costs.
217 Global evidence indicates women perform the majority of unpaid care work¹², which may
218 contribute to perceived opportunity gaps in competitive awards even where our measures
219 did not detect group differences.

220

221 Female physicians face significant career disadvantages due to the unequal distribution of
222 domestic labour, especially after motherhood¹³. Beyond the time diverted from professional
223 activities, mothers encounter the 'motherhood penalty,' a damaging cognitive bias that
224 assumes they are professionally less committed and competent after having children, while
225 fathers may experience a 'fatherhood bonus'¹⁴. Emerging evidence suggests that gender-
226 neutral career break policies in academia may inadvertently benefit men more than women,
227 as fathers are more likely to continue publishing during these 'career breaks' while mothers
228 do not¹⁵. Consequently, a gender-blind assessment of the effects of career breaks by award
229 assessment committees may overlook gender-specific productivity losses associated with

230 having children. Our findings underscore the importance of diversifying award assessment
231 committees, educating assessors about the unique career challenges faced by female
232 caregivers and the need for gender sensitive evaluation criteria. While including a 'relative to
233 opportunity' section on grants and prize applications is a positive step, assessors must be
234 equipped to truly understand and account for the sustained burden these responsibilities
235 specifically impose on a woman's career.

236 This study also identified a lack of opportunity as a key contributor to gender inequity
237 in rheumatology awards, with a lack of women nominees and few leadership opportunities
238 being highly scoring barriers. Connected to the nomination and selection process, the limited
239 visibility of deserving candidates was also considered a key factor, as was a lack of recognition
240 and valuation of women's work. Notably, more female respondents perceived the
241 undervaluation of women's work and lack of access to influential circles as critical factors than
242 male respondents. The exclusion of women from influential male-dominated circles
243 represents a subtle but profound barrier that is challenging to quantify and address. The
244 importance of social and professional connectedness in achieving professional success is
245 evident, given research demonstrating that awards concentrate within a highly connected
246 scientific elite⁹. Award recipients were more likely to identify the disproportionate allocation
247 of 'low visibility work' and higher attrition rates for women as crucial issues. It is possible that
248 these individuals, having successfully navigated the system, have a deeper awareness of the
249 systemic barriers.

250 Prizewinning is of critical importance not only to individuals and their institutions, but
251 also to the broader community, as it shapes future research investment. Therefore, it is
252 essential for award-granting institutions to accelerate progress towards equity.
253 Recommendations to achieve this include diversifying selection committees and award

254 nominee pools, advertising widely and enhancing the transparency of nomination and
255 selection⁸. These commendable suggestions seek to address some of the key barriers
256 identified in this survey. Nonetheless, the top-scoring factor amongst our survey respondents
257 pertains to the heavier burden of domestic responsibilities on women, which is not readily
258 remediable by a granting body. Reframing 'young investigator awards' as 'early career
259 awards', based on academic age rather than biological age⁸ and accurately assessing the
260 impact of career breaks and carer responsibilities will help. However, this deep-seated socio-
261 cultural inequity requires more comprehensive solutions beyond what granting bodies can
262 provide, including increasing men's participation in domestic responsibilities.

263 This study has several limitations. As a voluntary online survey, it carries the potential
264 for response bias, capturing the beliefs of a self-selected cohort within the rheumatology
265 profession. The overrepresentation of female respondents, who historically face greater
266 disparity in professional recognition, may have skewed the results. Notably, cultural factors
267 that discourage women from seeking leadership roles were not included as a response option,
268 potentially limiting the scope of factors identified. Societal norms and expectations around
269 ambition and power-seeking behaviours among women may discourage them from seeking
270 opportunities, further compounding disparities. The model to identify determinants of award
271 receipt was exploratory and limited by the self-reported nature of award status. The survey
272 was only available in English and respondents predominantly comprised rheumatologists,
273 with an under-representation of allied health professionals. While we asked about carer
274 responsibilities, we did not distinguish between primary and secondary caregiving roles,
275 which could have provided deeper insights into gender dynamics. Future research should aim
276 to broaden the respondent pool, include translations to capture non-English speakers, and
277 further explore the nuances of caregiving responsibilities. Nonetheless, this study is the first

278 to explore key factors driving gender inequity in global rheumatology awards, providing
279 meaningful insights and a foundation for future research and policy development.

280

281 **Conclusion**

282 This study sheds light on the barriers to achieving gender equity in prestigious rheumatology
283 awards, with the burden of domestic responsibilities and lack of professional opportunities
284 for women emerging as critical factors. Our results emphasise the need for award-granting
285 bodies to diversify selection committees, enhance transparency in the nomination process
286 and accurately assess career breaks and achievements relative to opportunity to address
287 gender-specific impacts on productivity.

288

289 **Acknowledgments**

290 The authors thank Japan College of Rheumatology (JCR), JCR Gender and Youth Equality
291 Committee, French Rheum Association (REF), Italian Rheumatology Society, Openreuma,
292 Spanish Rheumatology Society (SER), Portuguese Rheumatology Society (SPR), Greek
293 Rheumatology Society, Norwegian Society for Rheumatology, ERN Reconnect, Australian
294 Rheumatology Society, and OMERACT for their support. The authors also thank all
295 respondents for taking the survey.

296 **CHANGE Study Group Authors-** Elena Nikiphorou, Ghita Harifi, Humeira Badsha, Alejandra
297 Magdalena Babini, Joan Marie Von Feldt, Mariana Peixoto Guimarães Ubirajara E Silva de
298 Souza, Penélope Esther Palominos, Catherine Hill, Christina Duftner, Yoshiya Tanaka, Dr. Ran
299 Nakashima (Sasai), Dzifa Dey, Syed Atiq Haq, Ihsane Hmamouchi, Asgar Ali Kalla, Ho So, Iris J.
300 Colunga-Pedraza, Deshiré Alpizar-Rodríguez, Yi-Ming Chen, Babur Salim, Binit Vaidya, Ana
301 Maria Arredondo Gonzalez, Carlos Enrique Toro Gutiérrez, Wilson Bautista-Molano, Sadovici
302 Victoria, Dr. Qian Wang, Phonpen Akawatcharangura, Boonjing Siripaitoon, Bohdana
303 Doslaliuk, Syahrul Sazliyana Shahrir, Pierre-Antoine Juge, Laura Gossec, Uta Klitz, Johanna
304 Mucke, Prof. Vinod Ravindran, Vikas Aggarwal, Alexandros Panagiotopoulos, Jelena Colic,
305 Emre Bilgin, Ioannis Parodis, Manouk de Hooge, Sandra Tälli, Rosalie Magro, Eduardo
306 Dourado, Reem Hamdy, Nelly Ziade.

307 **Contribution of authors**

308 Conceptualisation: PO, LC, LG. Data curation: All authors. Formal analysis: LMR, JD. Funding
309 acquisition: N/A. Investigation: All authors. Methodology: All authors. Validation: All Authors,
310 Visualisation: All authors, Writing-original draft: JD, SS, LMR. Writing-review & editing: All
311 authors.

312 **Ethics approval**

313 Approval was obtained from the Sanjay Gandhi Postgraduate Institute of Medical Sciences
314 Ethics Review Board (226014).

315 **Consent for publication**

316 All the authors reviewed the final version of the manuscript and gave their consent for
317 publication.

318 **Declarations**

319 LC leads the EULAR GEAR group, LG serves as diversity, equity, and inclusivity ambassador for
320 Therapeutic advances and practice.

321 **Funding**

322 This study was not funded.

323 **Conflicts of Interest/Competing interests**

324 The authors have no COI relevant to this manuscript.

325 **Data availability statement**

326 All relevant data are present in this correspondence piece.

327 **Disclaimer**

328 No part of this manuscript is copied or published elsewhere in whole or in part.

329 **References**

- 330 1. Ovseiko PV, Gossec L, Andreoli L, Kiltz U, van Mens L, Hassan N, et al. Gender equity
331 in academic rheumatology, current status and potential for improvement: a cross-
332 sectional study to inform an EULAR task force. *RMD Open*. 2022 Aug;8(2):e002518.
333 doi: 10.1136/rmdopen-2022-002518.
- 334 2. Ross L, Bond S, Day JA. Pursuing Gender Equity in Rheumatology: Thinking Beyond
335 Gender Representation to Assess Gender Equality. *J Rheumatol*. 2025 Feb
336 1;52(2):112-115. doi:10.3899/jrheum.2024-0840.

- 337 3. Jorge A, Bolster M, Fu X, Blumenthal DM, Gross N, Blumenthal KG, Wallace Z. The
338 Association Between Physician Gender and Career Advancement Among Academic
339 Rheumatologists in the United States. *Arthritis Rheumatol*. 2021 Jan;73(1):168-172.
340 doi: 10.1002/art.41492.
- 341 4. Day J, Ovseiko P, Khursheed T, Titus R, Agarwal V, Coates L, Gupta L. Factors
342 impacting women's advancement to positions on editorial boards of rheumatology
343 journals. *Rheumatology (Oxford)*. 2023 Sep 1;62(9):e260-e262. doi:
344 10.1093/rheumatology/kead129.
- 345 5. Bagga E, Stewart S, Gamble GD, Hill J, Grey A, Dalbeth N. Representation of Women
346 as Authors of Rheumatology Research Articles. *Arthritis Rheumatol*. 2021
347 Jan;73(1):162-167. doi:10.1002/art.41490.
- 348 6. Monga K, Liew J. Gender gap in rheumatology: speaker representation at annual
349 conferences. *Ann Rheum Dis*. 2022 Nov;81(11):e238. doi: 10.1136/annrheumdis-
350 2020-217673.
- 351 7. Khursheed T, Harifi G, Ovseiko PV, Shekar HG, Badsha H, Gupta L. Is there a gender
352 gap in global rheumatology leadership? *Rheumatology (Oxford)*. 2023 Apr
353 3;62(4):e107-e108. doi: 10.1093/rheumatology/keac499.
- 354 8. Roy D, Andreoli L, Ovseiko PV, Dey D, Ravindran Y, Singla S, Arredondo González AM,
355 Toro-Gutiérrez CE, Gupta L. Gender equity in global rheumatology awards. *Ann*
356 *Rheum Dis*. 2024 Jun 12;83(7):958-959. doi: 10.1136/ard-2024-225670.
- 357 9. Ma Y, Uzzi B. Scientific prize network predicts who pushes the boundaries of science.
358 *Proc Natl Acad Sci U S A*. 2018 Dec 11;115(50):12608-12615. doi:
359 10.1073/pnas.1800485115.

- 360 10. Wang YS, Lee CJ, West JD, Bergstrom CT, Eroshva EA. Gender-based homophily in
361 collaborations across a heterogeneous scholarly landscape. PLoS One. 2023 Apr
362 5;18(4):e0283106. doi: 10.1371/journal.pone.0283106.
- 363 11. Eysenbach G. Improving the Quality of Web Surveys: The Checklist for Reporting
364 Results of Internet E-Surveys (CHERRIES). J Med Internet Res 2004;6(3):e34 URL:
365 <https://www.jmir.org/2004/3/e3> DOI: 10.2196/jmir.6.3.e34
- 366 12. OECD (2025), Gender Equality in a Changing World: Taking Stock and Moving
367 Forward, Gender Equality at Work, OECD Publishing,
368 Paris, <https://doi.org/10.1787/e808086f-en>.
- 369 13. Jolly S, Griffith KA, DeCastro R, Stewart A, Ubel P, Jagsi R. Gender differences in time
370 spent on parenting and domestic responsibilities by high-achieving young physician-
371 researchers. Ann Intern Med. 2014 Mar 4;160(5):344-53. doi: 10.7326/M13-0974.
- 372 14. Correll S, Benard S, Paik I. Getting a job: is there a motherhood penalty? Am J Sociol.
373 2007;112(5):1297-1338.
- 374 15. Antecol H, Bedard K, Stearns J. Equal but inequitable: who benefits from gender-
375 neutral tenure clock stopping policies? Am Econ Rev. 2018;108(9):2420-41.
376

377 Table 1

Gender (n=199/227)	
Cisgender male	66 (33.1%)
Cisgender female	136 (68.3%)
Agender	2 (1.0%)
Ethnicity (n=204/227)	
White	61 (29.9%)
Hispanic or Latino	89 (43.6%)
Black/African American	6 (2.9%)
East Asian (e.g., Chinese, Japanese, Korean)	20 (9.8%)
Southeast Asian (e.g., Vietnamese, Thai, Filipino)	7 (3.4%)
South Asian (e.g., Indian, Pakistani, Sri Lankan)	13 (6.3%)
Middle Eastern/North African	8 (3.9%)
Country of origin categorised by human development index (HDI) (n= 209/227)	
Low	10 (4.8%)
Medium	17 (8.1%)
High	96 (45.9%)
Very high	86 (41.1%)
Current relationship status (n=204/227)	
Single	28 (13.7%)
Never married	5 (2.4%)
Married/Cohabiting with partner	153 (75%)
Divorced/Separated	12 (5.8%)
Widowed	4 (1.9%)
Dependent care responsibilities such as children, sick parents, or sick spouse (n=204/227)	
No	88 (43.1%)
Yes	116 (56.8%)
Age (n=210/227)	
Below 30 years	14 (6.6%)
30-34 years	27 (12.8%)
35-39 years	42 (20%)
40-44 years	32 (15.2%)
45-49 years	34 (16.2%)
50-54 years	18 (8.6%)
55-59 years	14 (6.6%)
60 years or more	28 (13.3%)
Primary profession (n=209/227)	
Physician	198 (94.7%)
Nurse	1 (0.47%)
Physical/occupational therapist	1 (0.47%)
Psychologist	0
Social worker	0
Researcher (non- clinician)	5 (2.4%)
Others	0
Do you currently have an academic position? (n=209/227)	
No, I do not have an academic role	59 (28.2%)
Yes, Graduate student	23 (11%)
Yes - Postdoctoral fellow	13 (6.2%)
Yes - Assistant/Associate Professor or similar	70 (33.5%)
Yes - Full Professor	34 (16.2%)

Others	10 (4.8%)
As a physician, what is your current career stage? (n=208/227)	
Early career	59 (28.3%)
Mid-career	100 (48.1%)
Late career	49 (23.5%)
Have you received a prestigious career award or other eminent distinction in rheumatology? (n=211/227)	
No	139 (65.8%)
Yes, once	35 (16.6%)
Yes, more than once	26 (12.3%)
Not applicable	15 (7.2%)
Have you served on a selection committee for a prestigious career award or other eminent distinction in Rheumatology? (n=211/227)	
No	166 (78.6%)
Yes	30 (14.2%)
Not applicable	16 (7.6%)
How often have you seen a call/notification for nominations for rheumatology career awards or other eminent distinctions? (n=211/227)	
Never	85 (40.2%)
Once	43 (20.4%)
More than once	67 (31.7%)
Not applicable	33 (15.6%)
Have you nominated a colleague for a prestigious career award or other eminent distinction in rheumatology? (n=210/227)	
No, I haven't nominated anyone	104 (49.3%)
Yes, I have nominated a male colleague(s)	14 (6.6%)
Yes, I have nominated a female colleague(s)	19 (9.0%)
Yes, I have nominated both male and female colleagues	42 (19.9%)

378

379

380 **Figure 1.** Factors contributing to the under representation of women among recipients of
381 prestigious career awards in rheumatology (n=227)

382

383 Alt text: Bar chart illustrating responses to the question on key factors contributing to
384 underrepresentation of women among recipients of prestigious career awards in
385 rheumatology. The x-axis lists multiple factors grouped by color-coded themes, and the y-
386 axis shows the percentage of respondents. The highest responses cluster around
387 nomination bias, domestic responsibility burden, and career disruption barriers, suggesting
388 systemic and structural contributors to gender inequity in award recognition.


389

390

391

392

393



394
395
396
397

Supplementary Table 1. Exploratory logistic regression model for award receipt

Covariates	Odds ratio (95% CI)	p value
Female gender (vs male)	0.75 (0.34-1.66)	0.48
Profession (Physician vs allied health professional)	0.15 (0.01 - 1.64)	0.20
Having an academic position (vs none)	2.66 (1.01-7.03)	0.04
Late career stage (vs early career stage)	0.83 (0.16 – 4.36)	0.82
Caregiver responsibilities (vs none)	1.17 (0.49-2.78)	0.72
Medium/Low HDI (vs high)	0.35 (0.10 – 1.32)	0.12
Very high HDI (vs high)	0.66 (0.29 – 1.53)	0.34
Married/cohabiting with partner (vs not)	0.83 (0.34 - 2.03)	0.68
Member of award selection committee (vs not)	3.41 (1.13 – 10.27)	0.02
Age 50-60 years (vs <50 years)	2.29 (0.69 – 7.62)	0.18
Age >60 years (vs <50 years)	11.89 (2.29 – 61.8)	0.003

398 HDI- human development index

399

400 **Supplementary Table 2.** Exploratory logistic regression model for award receipt with
401 ethnicity included as covariate

402


Covariates	Odds ratio (95% CI)	p value
Female gender (vs male)	0.77 (0.35-1.71)	0.53
Profession (Physician vs allied health professional)	0.2 (0.01 – 1.46)	0.1
Having an academic position (vs none)	2.99 (1.07 – 8.31)	0.04
Late career stage (vs early career stage)	0.74 (0.14 – 4.0)	0.72
Caregiver responsibilities (vs none)	1.21 (0.50- 2.91)	0.67

Medium/Low HDI (vs high)	0.36 (0.10 – 1.34)	0.13
Very high HDI (vs high)	0.75 (0.30 – 1.83)	0.53
Married/cohabiting with partner (vs not)	0.79 (0.32 – 1.95)	0.60
Member of award selection committee (vs not)	3.44 (1.14 – 10.39)	0.03
Age 50-60 years (vs <50 years)	2.48 (0.73 – 8.42)	0.14
Age >60 years (vs <50 years)	13.62 (2.51 – 73.95)	0.002

HDI- human development index

403
404
405
406
407
408
409

Supplementary Figure 1: Conceptual directed acyclic graph for factors influencing award receipt



410
411
412

413

414

415

416

417

418

419

420

421 Coalition for Health and Gender Equity (CHANGE) Study Group – Complete Author List
422 and Affiliations

423 **Asia**

424 *United Arab Emirates*

425 1. **Ghita Harifi**: Rheumatology Unit, Department of Medicine, Dubai Hospital, Dubai,
426 United Arab Emirates. ghitaharifi@yahoo.fr

427 2. **Humeira Badsha** - doctorbadsha@gmail.com

428 *Japan*

429 1. **Yoshiya Tanaka**: The First Department of Internal Medicine, School of Medicine,
430 University of Occupational and Environmental Health, 1-1 Iseigaoka, Kitakyushu,
431 807-8555, Japan.: tanaka@med.uoeh-u.ac.jp

432 2. **Dr Ran Nakashima (Sasai)**- Department of Rheumatology and Clinical Immunology,
433 Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku,
434 Kyoto 606-8507, Japan ranran@kuhp.kyoto-u.ac.jp

435 *Bangladesh*

436 1. **Syed Atiq Haq**- Rheumatology, Green Life Center for Rheumatic Care and Research,
437 Dhaka, BGD

438 *Hong Kong*

439 1. **Dr. Ho So** - Assistant Professor, Department of Medicine & Therapeutics, Faculty of
440 Medicine, The Chinese University of Hong Kong, Hong Kong
441 h99097668@hotmail.com, hoso@cuhk.edu.hk

442 *Taiwan*

443 1. **Dr. Yi-Ming Chen** - Division of Allergy, Immunology and Rheumatology, Department
444 of Medical Research, Taichung Veterans General Hospital, Taiwan
445 blacklark@gmail.com

446 *Pakistan*

447 1. **Dr Babur Salim**- Rheumatology Department, Fauji Foundation Hospital,
448 Rawalpindi, Pakistan Orcid ID: 0000-0001-8430-9299. babursalim@yahoo.com

449 *Nepal*

450 1. **Dr Binit Vaidya**- Department of Rheumatology, National Centre for Rheumatic
451 Diseases, Ratopul, Kathmandu, Nepal drbinitvaidya@gmail.com

452 *China*

453 1. **Dr. Qian Wang** - Department of Rheumatology and Clinical Immunology, State Key
454 Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College
455 Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical
456 College, Beijing, China wangqian_pumch@126.com

457 *India*

458 1. **Prof. Vinod Ravindran** - Centre for Rheumatology, Calicut, Kerala, 2. Adjunct
459 Professor, Department of Medicine, Kasturba Medical College, Manipal, Karnataka, India.
460 drvinod12@gmail.com.

461 2. **Prof. Vikas Aggarwal**- Department of Clinical Immunology and Rheumatology, Sanjay
462 Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. Orcid ID: 0000-0002-
463 4508-1233. vikasagr@yahoo.com

464 3. **Dr. Vishwesh Agarwal** - Mahatma Gandhi Mission Medical College, Navi Mumbai,
465 Maharashtra, India. vishwesh002@gmail.com

466 4. **Manali Sarkar**- Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai,
467 Maharashtra, India manalisarkar12@gmail.com

468 5. **Taanya Talreja**- Seth GS Medical College and KEM Hospital, Mumbai, India.
469 taanyatalreja@gmail.com

470 *Thailand*

471 1. **Phonpen Akawatcharangura** - Department of Medicine, Queen Savang Vadhana
472 Memorial Hospital, Chonburi, Thailand phonpen@msn.com.

473 2. **Boonjing Siripaitoon** - Division of Allergy and Rheumatology, Department of Internal
474 Medicine, Prince of Songkla University, HatYai, Songkhla, Thailand, 90110
475 boonjing39@yahoo.com

476 3. **Kanon Jatuworapruk**- Faculty of Medicine, Thammasat University, Pathum Thani,
477 THAILAND kanon@tu.ac.th

478 *Malaysia*

479 1. **Syahrul Sazliyana Shaharir** - Rheumatology Unit, Department of Internal Medicine,
480 Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Jalan Yaacob Latiff, Kuala
481 Lumpur, Malaysia ssazliyana@gmail.com

482 *Philippines*

483 1. **Lisa Traboco**- 1. St Luke's Medical Center-Global City, Philippines. 2. University of
484 the Philippines, Manila, Philippines. lisatraboco@gmail.com

485

486 *Kazakhstan*

487 1. **Galym Togizbayev**- Kazakh National Medical University: Almaty, Kazakhstan
488 g.togizbayev@gmail.com

489 *Turkey*

490 1. **Emre Bilgin** - Division of Rheumatology, Department of Internal Medicine, Faculty of
491 Medicine, Hacettepe University, Ankara, Turkey dr.emrebilgin@gmail.com.

492 *Lebanon*

493 1. **Nelly Ziadé** - Rheumatology Department, Hôtel-Dieu de France Hospital, Saint
494 Joseph's University, Beirut, Lebanon drnellyziade@gmail.com, nellziade@yahoo.fr

495

496 **North America**

497 *United States*

498 1. **Joan Marie Von Feldt** -University of Pennsylvania, Philadelphia, PA, USA.
499 joan.vonfeldt@gmail.com

500 2. **Grace Wright**: Association of Women in Rheumatology, 345 E 37th Street, Suite 303C,
501 New York, NY 10016

502 *Mexico*

503 1. **Dr. Iris J. Colunga-Pedraza** - Rheumatology Service, Facultad de Medicina y Hospital
504 Universitario "Dr. JoseE. Gonzalez", Universidad Autonoma de Nuevo Leon, Av.
505 Francisco I. iriscolunga@hotmail.com

506 2. **Deshiré Alpizar-Rodríguez**- Division of Rheumatology, University Hospital of Geneva,
507 26 Ave Beau-Sejour, CH 1211 Geneva, Switzerland. deshire_alpizar@hotmail.com

508 **South America**

509 *Argentina*

510 1. **Alejandra Magdalena Babini**- Rheumatology Unit, Hospital Italiano de Cordoba,
511 Cordoba, Argentina. Email: alebabini@gmail.com

512 *Brazil*

513 1. **Mariana Peixoto Guimarães Ubirajara E Silva de Souza** -Post Graduate Program in
514 Sciences Applied to Adult Health Care, Federal University of Minas Gerais, Av. Prof.

515 Alfredo Balena, 190 - Santa Efigênia, Belo Horizonte, Minas Gerais, 30130-100, Brazil .
516 marianapagus@yahoo.com.br

517 2. **Penélope Esther Palomino**^{s 1}Universidade Federal do Rio Grande do Sul (UFRGS),
518 Programa de Pós Graduação em Ciências Médicas (PPGCM), Rua Ramiro Barcelos
519 2400, segundo andar, Porto Alegre, 90035-903, Brazil.

520 penelopepalominos@gmail.com.2. Department of Rheumatology, Hospital de
521 Clinicas de Porto Alegre, Rua Ramiro Barcelos 2350, sexto andar, Porto Alegre,
522 90035-903, Brazil. penelopepalominos@gmail.com.

523 3. **Júlia Boechat Farani**: Pontifícia Universidade Católica do Rio Grande do Sul, Porto
524 Alegre (RS), Brazil

525 *Columbia*

526 1. **Dr. Ana Maria Arredondo Gonzalez** – 1. Colombian Association of Rheumatology,
527 Bogotá, Colombia; 2. Department of Rheumatology, Faculty of Medicine, Fundación
528 Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia

529 2. **Dr. Carlos Enrique Toro Gutiérrez**- General Director, Reference Center for
530 Osteoporosis, Rheumatology and Dermatology, Pontifica Universidad Javeriana Cali,
531 Colombia. carlostororeumatologo@gmail.com. ORCID: 0000-0002-6084-7049

532
533 3. **Wilson Bautista-Molano**: 1. Clinical Immunology Group, Universidad Militar Nueva
534 Granada, Bogotá, Colombia. 2. Cellular and Molecular Immunology Group (InmuBo),
535 Universidad El Bosque, Bogotá, Colombia. 3. Department of Rheumatology, Hospital
536 Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia. ORCID: 0000-0003-
537 0684-9542. wilson.bautista@gmail.com

538 **Africa**

539 *Cameroon*

540 1. **Dr Fernando Kemta Lekpa** - 1 Department of Internal Medicine and Specialties,
541 Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang,
542 Cameroon 2 Department of Internal Medicine, Douala General Hospital, Douala,
543 Cameroon. fklekpa@yahoo.fr. ORCID: 0000-0001-7592-5049

544 *Niger*

545 1. **Dr Moussa Elh Ibrahim Fanata**: Head of the Rheumatology Department, Niamey
546 National Hospital, Niger. fanatamoussa@yahoo.fr

547 *Rwanda*

548 1. **Dr Mubirigi Alexandre**: Pediatrician, Kacyiru Police Hospital, Kigali, Rwanda.
549 mubiralex@gmail.com ORCID: 0000-0003-3413-9855.

550 *Algeria*

551 **1. Dr Chafia Dahou Makhloufi** - professor in rheumatology, faculty of medicine. Bab El
552 Oued University Hospital, Algiers, Algeria. makhloufi-dahou@hotmail.com. ORCID:
553 0000-0002-6523-9851

554 *Kenya*

555 **1. Dr Eugene Kalman Genga** - Lecturer at University of Nairobi.
556 eugenekalman@gmail.com. ORCID: 0000-0001-5866-7105

557 *Ghana*

558 **1. Dr Dzifa Dey**- Department of Medicine and Therapeutics, University of Ghana School
559 of Medicine and Dentistry, College of Health Sciences, Korle-Bu, Accra, Ghana.
560 drdzifadey@gmail.com. ORCID: 0000-0002-3339-5112.

561 *Morocco*

562 **1. Dr Ihsane Hmamouchi**- 1. Health Sciences Research Centre (CRess), Morocco.
563 2.Faculty of Medicine, International University of Rabat (UIR), Morocco.
564 ihsane.hmamouchi@gmail.com. ORCID: 0000-0003-4402-5034.

565 *South Africa*

566 **1. Prof. Asgar Ali Kalla**- Chief of Rheumatology Unit, Groote Schuur
567 Hospital.kalla@iafrica.com

568 **Europe**

569 *Denmark*

570 **1. Anne Margrethe Troldborg** Rheumatology, Aarhus University Hospital, Aarhus,
571 Denmark annetrol@rm.dk. 2. Biomedicine, Aarhus University, Aarhus, Denmark.
572 annetrol@rm.dk

573 *Croatia*

574 **1. Dr. Ivan Padreja**- Division of Clinical Immunology and Rheumatology, Department
575 of Internal Medicine, University Hospital Centre Zagreb, University of Zagreb School of
576 Medicine. ivan_padjen@yahoo.ca. ORCID: 0000-0002-9249-9325

577 *Cyprus*

578 **1. Dr Konstantinos Parperis** - University of Cyprus Medical School.
579 kparpe02@ucy.ac.cy. ORCID: 0000-0001-6009-0130

580 *Netherlands*

581 1. **Dr Luis Fernando Perez Garcia:** Department of Rheumatology, Erasmus Medical
582 Center, Rotterdam, Netherlands. ORCID: 0000-0002-8958-9493 l.perez@erasmusmc.nl

583 *Russia*

584 **Dr Margarita Aleksandrovna Gromova,** Pirogov Russian National Research Medical
585 University (RNRMU), Moscow, Russian Federation. margarita-gromov@mail.ru ORCID: 0000-
586 0002-3757-058X

587 *Belarus*

588 1. **Dr Marharyta Volkava:** Belarusian Medical Academy of Post-Graduate Education,
589 Minsk, Republic of Belarus. ORCID: 0000-0001-8572-9252. margovolkova@gmail.com

590 *United Kingdom*

591 1. **Dr Elena Nikiphorou-** 1. Centre for Rheumatic Diseases, King's College London,
592 London, UK. 2. Rheumatology Department, King's College Hospital, London, UK. ORCID:
593 0000-0001-6847-3726. enikiphorou@gmail.com

594 2. **Pavel Ovseiko:** Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

595 3. **Laura Coates:** Nuffield Department of Orthopaedics, Rheumatology and
596 Musculoskeletal Sciences, University of Oxford, Oxford, UK

597 4. **Latika Gupta:** 1. Department of Rheumatology, Royal Wolverhampton Hospitals
598 NHS Trust, Wolverhampton, UK. 2. Division of Musculoskeletal and Dermatological
599 Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science
600 Centre, The University of Manchester, Manchester, United Kingdom. ORCID: 0000-0003-
601 2753-2990.

602 5. **Neelam Hassan-** MRC Clinical Research Fellow - University of Bristol Honorary
603 Rheumatology Registrar- North Bristol NHS Trust neelam.hassan@bristol.ac.uk

604 6. **Anne-Marie Russell-** School of Health Sciences, College of Medicine and Health,
605 University of Birmingham, UK. a.russell.1@bham.ac.uk

606 *Italy*

607 1. **Laura Andreoli:** Rheumatology and Clinical Immunology Unit, ASST Spedali, Civili and
608 University of Brescia, 25123, Brescia, Italy.

609 *Austria*

610 1. **Christina Duftner** -Department of Internal Medicine, Clinical Division of Internal
611 Medicine II, Medical University of Innsbruck, Innsbruck, Tirol, Austria
612 christina.duftner@gmx.at. christina.duftner@i-med.ac.at

613 *Republic of Moldova*

614 1. **Dr. Sadovici Victoria** – 1. Department of Internal Medicine, State University of
615 Medicine and Pharmacy “Nicolae Testimiteanu”, Chisinau, Republic of Moldova; 2.
616 Medpark International Hospital, Chisinau, Republic of Moldova Victoria.Sadovici-
617 bobecia@usmf.md

618 *Ukraine*

619 1. **Bohdana Doslaliuk** - Department of pathophysiology, Ivano-Frankivsk National
620 Medical University Ivano-Frankivsk, Ukraine Doslaliuk_Bo@ifnmu.edu.ua

621 *France*

622 1. **Pierre-Antoine Juge** - Dept of Rheumatology, DMU Locomotion, INSERM UMR1152,
623 Hôpital Bichat-Claude Bernard, APHP, Université de Paris, Paris, France.
624 pierreantoine.juge@aphp.fr
625 2. **Laura Gossec**- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et
626 de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP, Rheumatology Department,
627 Paris, France. laure.gossec@aphp.f

628 *Germany*

629 1. **Uta Klitz** - Rheumazentrum Ruhrgebiet, Herne; Rheumatologie, Universitätsmedizin
630 Charité, Berlin, Germany.J. Braun, MD, Professor; X. Baraliakos, MD; U. Klitz, MD; F.
631 Heldmann, MD; Rheumazentrum Ruhrgebiet; J. Sieper, MD, Professor,
632 Rheumatologie, Universitätsmedizin Charité. Uta.Kiltz@elisabethgruppe.de
633 2. **Johanna Mucke** - Poliklinik, Funktionsbereich und Hiller-Forschungszentrum für
634 Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225,
635 Düsseldorf, Deutschland johanna.mucke@med.uni-duesseldorf.de

636 *Greece*

637 1. **Alexandros Panagiotopoulos** - Rheumatology Unit, First Department of
638 Propaedeutic Internal Medicine Medical School, National and Kapodistrian
639 University Laiko General Hospital, Athens, Greece alej.panagiotopoulos@gmail.com

640 *Serbia*

641 1. **Jelena Colic** - Department of Rheumatology, Institute of Rheumatology, Belgrade,
642 Serbia jcolicster@gmail.com

643 *Sweden*

644 1. **Ioannis Parodis** - Division of Rheumatology, Department of Medicine Solna,
645 Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
646 ioannis.parodis@ki.se

647 *Spain*

648 1. **Cristiana Sieiro Santos**: Consultant Rheumatology at Complejo Asistencial
649 Universitario de León (Spain) cristysieirosantos@gmail.com

- 650 *Belgium*
- 651 1. **Manouk de Hooge** - Department of Rheumatology, Ghent University Hospital,
- 652 Ghent, Belgium; VIB Center of Inflammation Research, Ghent University, Ghent,
- 653 Belgium. msmdehooge@gmail.com
- 654 *Estonia*
- 655 1. **Sandra Tälli**- Department of Rheumatology, East Tallinn Central Hospital, Tallinn,
- 656 Estonia. sandra.talli@gmail.com
- 657 *Malta*
- 658 1. **Rosalie Magro** - Rheumatology Department, Mater Dei Hospital, Tal-Qroqq, Msida,
- 659 MSD, 2090, Malta. rosaliemagro@gmail.com.
- 660 *Portugal*
- 661 1. **Eduardo Dourado** - Rheumatology Department, Centro Hospitalar do Baixo Vouga,
- 662 3810-164 Aveiro, Portugal eduardojorgedd@gmail.com
- 663 **Australia**
- 664 *Australia*
- 665 1. **Catherine Hill**- 1. The University of Adelaide, Adelaide, South Australia, Australia 2.
- 666 Department of Rheumatology, The Queen Elizabeth Hospital, Woodville South, South
- 667 Australia, Australia. catherine.hill@sa.gov.au
- 668 2. **Jessica Day**: Department of Rheumatology, Royal Melbourne Hospital, Parkville, VIC
- 669 3050, Australia.2. Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052
- 670 Australia. 3. Department of Medical Biology, University of Melbourne, Parkville, VIC
- 671 3052 Australia.
- 672 3. **Tracey Rudd**: Australian Rheumatology Association.
- 673 Tracey.Rudd@rheumatology.org.au
- 674
- 675

676 **Coalition for Health and Gender Equity (CHANGE) Study Group – Complete**

677 **Acknowledgments List**

- 678 - Japan College of Rheumatology (JCR)
- 679 - JCR Gender and Youth Equality Committee
- 680 - French Rheum Association (REF)
- 681 - Italian Rheumatology Society

- 682 - Openreuma
- 683 - Spanish Rheumatology Society (SER)
- 684 - Portuguese Rheumatology Society (SPR)
- 685 - Greek rheumatology society
- 686 - Norwegian Society for Rheumatology
- 687 - ERN Reconnect
- 688 - Australian Rheumatology Society
- 689 - OMERACT
- 690
- 691
- 692
- 693
- 694
- 695
- 696